FDA Approves AbbVie’s Subcutaneous SKYRIZI Induction for Crohn’s Disease

The FDA approved a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn’s disease, allowing patients to begin treatment at home.